AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1775610 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ECT (BL)
Number of subjects: 0
Study 7068295 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling at 3500 m ASL
Number of subjects: 3
Study 31374304 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingenol mebutate (IngMeb) 0.027%
Number of subjects: 0
Study 31374304 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study 31061111 — intervention group
Group type: EXPERIMENTAL
Intervention: Active superior cluneal nerve block
Number of subjects: 20
Study 31061111 — intervention group
Group type: COMPARATOR
Intervention: Placebo block
Number of subjects: 20
Study 29087167 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive outreach cessation intervention
Number of subjects: 2406
Study 27250120 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA emulsion (60 mg/kg/day)
Number of subjects: 1244
Study 27250120 — intervention group
Group type: COMPARATOR
Intervention: Control emulsion without DHA
Number of subjects: 1244
Study 24378629 — intervention group
Group type: EXPERIMENTAL
Intervention: SpineCor brace
Number of subjects: 38
Study 24378629 — intervention group
Group type: COMPARATOR
Intervention: Rigid brace
Number of subjects: 38
Study 21927836 — intervention group
Group type: EXPERIMENTAL
Intervention: LCE 125 mg after LCE 150 mg
Number of subjects: 19
Study 21927836 — intervention group
Group type: COMPARATOR
Intervention: LCE 100 mg
Number of subjects: 19
Study 19506174 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate, high-vegetable protein diet (26% of total calories, 31% from gluten, soy, nuts, fruits, vegetables, and cereals, 43% vegetable oil)
Number of subjects: 47
Study 19506174 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate lacto-ovo vegetarian diet (58% carbohydrate, 16% protein, 25% fat)
Number of subjects: 47
Study 17452165 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise oscillatory breathing (EOB)
Number of subjects: 288
Study 17452165 — intervention group
Group type: EXPERIMENTAL
Intervention: VE/VCO2 slope (threshold, < 36.2 or >= 36.2)
Number of subjects: 288
Study 17452165 — intervention group
Group type: EXPERIMENTAL
Intervention: EOB and VE/VCO2 slope combination
Number of subjects: 288
Study 14991240 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial volume correction (PVC) with global mean normalization
Number of subjects: 122
Study 14991240 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial volume correction (PVC) with cerebellar normalization
Number of subjects: 122
Study 14991240 — intervention group
Group type: COMPARATOR
Intervention: No PVC (control group)
Number of subjects: 122
Study 12568481 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate therapy
Number of subjects: 0
Study 12568481 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 0
Study 9524826 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulbactam/cefoperazone (2 g/4 g every 12 hours)
Number of subjects: 203
Study 9524826 — intervention group
Group type: COMPARATOR
Intervention: Imipenem (500 mg every 6 hours)
Number of subjects: 203
Study 8580951 — intervention group
Group type: EXPERIMENTAL
Intervention: Stair-climbing ergometry at 75% of predicted VO2max for 22 minutes
Number of subjects: 0
Study 2504834 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxithromycin (RU) at a daily dosage of 300 mg
Number of subjects: 209
Study 2504834 — intervention group
Group type: COMPARATOR
Intervention: Josamycin (JM) at a daily dosage of 1200 mg
Number of subjects: 209
Study 2504834 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxithromycin (RU)
Number of subjects: 209
Study 2504834 — intervention group
Group type: COMPARATOR
Intervention: Josamycin (JM)
Number of subjects: 209
Study 1060748 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine (positive control)
Number of subjects: 0
Study 1060748 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing
Number of subjects: 0
Study 1060748 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no specific agent mentioned)
Number of subjects: 0
Study 1060748 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis group (no calculus at start)
Number of subjects: 0
Study 30080982 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear appeal messages with high threat and high efficacy
Number of subjects: 488
Study 30080982 — intervention group
Group type: COMPARATOR
Intervention: Fear appeal messages with varying levels of threat and efficacy
Number of subjects: 488
Study 30080982 — intervention group
Group type: COMPARATOR
Intervention: Fear appeal messages across traditional and social media
Number of subjects: 488
Study 30169183 — intervention group
Group type: EXPERIMENTAL
Intervention: Appointment management intervention
Number of subjects: 120
Study 30169183 — intervention group
Group type: COMPARATOR
Intervention: Current care (control)
Number of subjects: 120
Study 25303024 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ablative fractional photothermolysis (FP) using a fractional 1550-nm ytterbium/erbium fibre laser, delivered four times at 4-week intervals.
Number of subjects: 30
Study 25303024 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ablative fractional photothermolysis (FP)
Number of subjects: 30
Study 25303024 — intervention group
Group type: COMPARATOR
Intervention: Control group (lesions on the other side of the body)
Number of subjects: 30
Study 23504039 — intervention group
Group type: EXPERIMENTAL
Intervention: toltrazuril (MTol)
Number of subjects: 40
Study 23504039 — intervention group
Group type: COMPARATOR
Intervention: Control (NegC)
Number of subjects: 40
Study 21402547 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (400 mg twice daily)
Number of subjects: 30
Study 21402547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 17849380 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiation therapy
Number of subjects: 908
Study 17849380 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiation therapy with postoperative anastomotic leakage
Number of subjects: 908
Study 17849380 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 908
Study 16598975 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented recession of the medial rectus muscles
Number of subjects: 28
Study 16598975 — intervention group
Group type: EXPERIMENTAL
Intervention: Faden procedure (recession of both medial rectus muscles and posterior fixation suture)
Number of subjects: 28
Study 16598975 — intervention group
Group type: EXPERIMENTAL
Intervention: Slanted recession of both medial rectus muscles
Number of subjects: 28
Study 12828501 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan nasal spray 5.0 mg
Number of subjects: 1547
Study 12828501 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan nasal spray 2.5 mg
Number of subjects: 1547
Study 12828501 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan nasal spray 1.0 mg
Number of subjects: 1547
Study 12828501 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan nasal spray 0.5 mg
Number of subjects: 1547
Study 12828501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1547
Study 10871909 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonate therapy
Number of subjects: 152
Study 9420131 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 51
Study 9420131 — intervention group
Group type: COMPARATOR
Intervention: Immunotherapy
Number of subjects: 51
Study 8508996 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilvadipine 8 or 16 mg once daily
Number of subjects: 307
Study 8508996 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine t.i.d.
Number of subjects: 307
Study 3521557 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical carbonic anhydrase inhibitor (aminozolamide) - 50 microL gel application
Number of subjects: 18
Study 3521557 — intervention group
Group type: COMPARATOR
Intervention: Untreated control eye
Number of subjects: 18
Study 31481555 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyle Program (HeLP)
Number of subjects: 0
Study 31481555 — intervention group
Group type: COMPARATOR
Intervention: Usual care (physiotherapy)
Number of subjects: 0
Study 27602508 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin
Number of subjects: 78
Study 27602508 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 78
Study 27602508 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-hyperfractionated cyclophosphamide, vincristine, and doxorubicin plus inotuzumab
Number of subjects: 78
Study 27602508 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD negativity in S1
Number of subjects: 78
Study 27602508 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD negativity in S2
Number of subjects: 78
Study 27602508 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (SCT) in S1
Number of subjects: 78
Study 27602508 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (SCT) in S2
Number of subjects: 78
Study 25341478 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB-H (losartan 50 mg and hydrochlorothiazide 12.5 mg)
Number of subjects: 42
Study 25341478 — intervention group
Group type: COMPARATOR
Intervention: Control (amlodipine 2.5 mg daily)
Number of subjects: 42
Study 25341478 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (including amlodipine 2.5 mg daily)
Number of subjects: 42
Study 22681743 — intervention group
Group type: EXPERIMENTAL
Intervention: $25 shopping voucher for attending cardiovascular risk assessment
Number of subjects: 301
Study 22681743 — intervention group
Group type: COMPARATOR
Intervention: No monetary incentive (control group)
Number of subjects: 301
Study 19528204 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (12 weeks treatment)
Number of subjects: 94
Study 19528204 — intervention group
Group type: COMPARATOR
Intervention: Control (NGT)
Number of subjects: 94
Study 17289483 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) 0.6 mg/kg
Number of subjects: 78
Study 17289483 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 78
Study 17289483 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX)
Number of subjects: 78
Study 12574871 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (weight bearing and resistance exercise)
Number of subjects: 90
Study 12574871 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training + HRT
Number of subjects: 90
Study 12574871 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 90
Study 12574871 — intervention group
Group type: COMPARATOR
Intervention: No exercise (Control group)
Number of subjects: 90
Study 12574871 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (in women not taking HRT)
Number of subjects: 90
Study 12574871 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 90
Study 10956570 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 10
Study 10956570 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 10
Study 10956570 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 10
Study 8831595 — intervention group
Group type: EXPERIMENTAL
Intervention: albumin
Number of subjects: 289
Study 8831595 — intervention group
Group type: EXPERIMENTAL
Intervention: dextran 70
Number of subjects: 289
Study 8831595 — intervention group
Group type: EXPERIMENTAL
Intervention: polygeline
Number of subjects: 289
Study 1450496 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.7 x 10(6) I.U. of tPA (group B)
Number of subjects: 30
Study 1450496 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 x 10(6) I.U. of tPA (group C)
Number of subjects: 30
Study 1450496 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone (group A)
Number of subjects: 30
Study 6541387 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine (PPA) 50 mg p.o. twice daily
Number of subjects: 20
Study 6541387 — intervention group
Group type: EXPERIMENTAL
Intervention: Estriol vaginal suppositories 1 mg daily
Number of subjects: 20
Study 6541387 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with PPA and estriol
Number of subjects: 20
Study 6541387 — intervention group
Group type: COMPARATOR
Intervention: Control (initial values)
Number of subjects: 20
Study 3781985 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine infusion (70-80 micrograms X kg‐1 X min‐1)
Number of subjects: 6
Study 3781985 — intervention group
Group type: COMPARATOR
Intervention: Control saline infusion
Number of subjects: 6
Study 30238915 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg)
Number of subjects: 59
Study 30238915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 28274273 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-myofascial release (SMR) - one session of 2×60 s at the anterior thigh
Number of subjects: 16
Study 28274273 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive static stretching - one session of 2×60 s of passive static stretching of the anterior thigh
Number of subjects: 16
Study 28274273 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 16
Study 27018030 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Anesthetic and Ketamine (LAK)
Number of subjects: 60
Study 27018030 — intervention group
Group type: COMPARATOR
Intervention: Local Anesthetic Alone (LAA)
Number of subjects: 60
Study 23983593 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 µg/kg dexmedetomidine
Number of subjects: 132
Study 23983593 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 µg/kg dexmedetomidine
Number of subjects: 132
Study 23983593 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 µg/kg dexmedetomidine
Number of subjects: 132
Study 23983593 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline (control group S)
Number of subjects: 132
Study 20505177 — intervention group
Group type: EXPERIMENTAL
Intervention: RVPA shunt
Number of subjects: 549
Study 20505177 — intervention group
Group type: COMPARATOR
Intervention: MBT shunt
Number of subjects: 549
Study 18254808 — intervention group
Group type: EXPERIMENTAL
Intervention: LED treatment
Number of subjects: 15
Study 18254808 — intervention group
Group type: COMPARATOR
Intervention: Untreated side (Control)
Number of subjects: 15
Study 16482072 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterol ester enriched margarine
Number of subjects: 41
Study 16482072 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant stanol ester enriched margarine
Number of subjects: 41
Study 16482072 — intervention group
Group type: COMPARATOR
Intervention: Control margarine
Number of subjects: 41
Study 12673257 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 80
Study 12673257 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 80
Study 11093999 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine 10 mg
Number of subjects: 80
Study 11093999 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 10 mg + fentanyl 25 microg
Number of subjects: 80
Study 11093999 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 7.5 mg + fentanyl 25 microg
Number of subjects: 80
Study 11093999 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 5 mg + fentanyl 25 microg
Number of subjects: 80
Study 9420535 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrowband UV-B
Number of subjects: 22
Study 9420535 — intervention group
Group type: COMPARATOR
Intervention: Broadband UV-B
Number of subjects: 22
Study 1543190 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematocrit maintained at 0.35
Number of subjects: 20
Study 1543190 — intervention group
Group type: COMPARATOR
Intervention: Hematocrit maintained at 0.45
Number of subjects: 20
Study 2859924 — intervention group
Group type: EXPERIMENTAL
Intervention: maytansine
Number of subjects: 105
Study 2859924 — intervention group
Group type: EXPERIMENTAL
Intervention: low-dose chlorozotocin (120 mg/m2)
Number of subjects: 105
Study 2859924 — intervention group
Group type: EXPERIMENTAL
Intervention: high-dose chlorozotocin (175 mg/m2)
Number of subjects: 105
Study 31806100 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatry specialty with COI
Number of subjects: 1729
Study 31806100 — intervention group
Group type: COMPARATOR
Intervention: General specialties with COI
Number of subjects: 1729
Study 31806100 — intervention group
Group type: EXPERIMENTAL
Intervention: Desire for COI information
Number of subjects: 1729
Study 31806100 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuing care due to COI
Number of subjects: 1729
Study 31806100 — intervention group
Group type: EXPERIMENTAL
Intervention: Age older than 34 years
Number of subjects: 1729
Study 31806100 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonwhite race
Number of subjects: 1729
Study 31806100 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational attainment of 4 or more years of college
Number of subjects: 1729
Study 31806100 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician specialty as a psychiatrist
Number of subjects: 1729
Study 30354990 — intervention group
Group type: EXPERIMENTAL
Intervention: Active repetitive transcranial magnetic stimulation (1 Hz)
Number of subjects: 199
Study 30354990 — intervention group
Group type: COMPARATOR
Intervention: Sham repetitive transcranial magnetic stimulation
Number of subjects: 199
Study 30354990 — intervention group
Group type: EXPERIMENTAL
Intervention: Active repetitive transcranial magnetic stimulation
Number of subjects: 199
Study 27569824 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (3 g/L)
Number of subjects: 90
Study 27569824 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (6 g/L)
Number of subjects: 90
Study 27569824 — intervention group
Group type: COMPARATOR
Intervention: Control (no L-carnitine)
Number of subjects: 90
Study 23519822 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehmannia glutinosa acteosides (two 200‐mg capsules, bid) and irbesartan (one 150‐mg tablet, qd)
Number of subjects: 479
Study 23519822 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan (one 150‐mg tablet, qd)
Number of subjects: 479
Study 23519822 — intervention group
Group type: COMPARATOR
Intervention: Both treatment and control groups
Number of subjects: 479
Study 22854403 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal protein load of 0.5 kcal/min
Number of subjects: 16
Study 22854403 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal protein load of 1.5 kcal/min
Number of subjects: 16
Study 22854403 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal protein load of 3 kcal/min
Number of subjects: 16
Study 22854403 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 16
Study 20386016 — intervention group
Group type: EXPERIMENTAL
Intervention: RO5068760 50 mg
Number of subjects: 48
Study 20386016 — intervention group
Group type: EXPERIMENTAL
Intervention: RO5068760 100 mg
Number of subjects: 48
Study 20386016 — intervention group
Group type: EXPERIMENTAL
Intervention: RO5068760 200 mg
Number of subjects: 48
Study 20386016 — intervention group
Group type: EXPERIMENTAL
Intervention: RO5068760 400 mg
Number of subjects: 48
Study 20386016 — intervention group
Group type: EXPERIMENTAL
Intervention: RO5068760 600 mg
Number of subjects: 48
Study 20386016 — intervention group
Group type: EXPERIMENTAL
Intervention: RO5068760 800 mg
Number of subjects: 48
Study 20386016 — intervention group
Group type: EXPERIMENTAL
Intervention: RO5068760 (all doses)
Number of subjects: 48
Study 19115449 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate progress feedback to therapists
Number of subjects: 1101
Study 19115449 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual-based Clinical Support Tool (CST)
Number of subjects: 1101
Study 19115449 — intervention group
Group type: COMPARATOR
Intervention: 1-week delayed CST feedback
Number of subjects: 1101
Study 19115449 — intervention group
Group type: COMPARATOR
Intervention: 2-week delayed CST feedback
Number of subjects: 1101
Study 19115449 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual control group
Number of subjects: 1101
Study 19115449 — intervention group
Group type: COMPARATOR
Intervention: Delayed progress feedback and CST feedback group
Number of subjects: 1101
Study 16306502 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric training program
Number of subjects: 27
Study 16306502 — intervention group
Group type: COMPARATOR
Intervention: Basic resistance training program
Number of subjects: 27
Study 12897739 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab (0.7 mg/kg conditioning dose followed by 7 weekly doses of 2.0 mg/kg)
Number of subjects: 35
Study 12897739 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab
Number of subjects: 35
Study 12897739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 11391843 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2a monotherapy at a maintenance dose of 9 MIU daily for 12 months
Number of subjects: 17
Study 11391843 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2a monotherapy
Number of subjects: 17
Study 8855830 — intervention group
Group type: EXPERIMENTAL
Intervention: Benfluorex (150 mg/tablet)
Number of subjects: 29
Study 8855830 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 tablets/day)
Number of subjects: 29
Study 1516390 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 ml of 2.5 percent cocaine by intratracheal injection (TI) (n = 18)
Number of subjects: 53
Study 1516390 — intervention group
Group type: COMPARATOR
Intervention: Bronchoscopic injection of cocaine (BI) (n = 19)
Number of subjects: 53
Study 1516390 — intervention group
Group type: COMPARATOR
Intervention: 4 ml of 4 percent lidocaine delivered by nebulizer (NEB) (n = 16)
Number of subjects: 53
Study 6231942 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical clindamycin phosphate (1% solution) twice daily
Number of subjects: 0
Study 6231942 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide (5% gel) twice daily
Number of subjects: 0
Study 6231942 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide (5% gel) in the morning and clindamycin phosphate (1% solution) in the evening
Number of subjects: 0